The study involved more than 800 patients who have weight-related comorbidities not related to Type 2 diabetes. For 12 weeks, the participants engaged in an “intensive lifestyle intervention” that included a low-calorie diet, exercise and frequent counseling sessions, Eli Lilly said in an Oct. 15 news release.
About 580 people lost at least 5% of their weight after the 12 weeks, and among that cohort, they were split between taking Mounjaro or a placebo. After 84 weeks, participants who took Mounjaro lost, on average, 26.6% of their weight — equal to 64.4 pounds each. The placebo group achieved a 3.8% weight loss, or nine pounds. Eli Lilly said the results show Mounjaro’s “superiority” over a placebo.
The most common side effects were “gastrointestinal-related and generally mild to moderate in severity,” the drugmaker said.
The therapy is a glucagon-like peptide-1 receptor agonist, which is the same medication class as two popular Novo Nordisk medications: Type 2 diabetes drug Ozempic and weight loss therapy Wegovy.
The FDA and European Medicines Agency are currently evaluating whether to approve Mounjaro as a weight loss drug.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
